Is USP enough for commercial PET production?

No. covers compounding and investigational use; commercial NDA/ANDA distribution requires 212. FDA references within 212 for specific tests (radiochemical identity, radionuclidic purity), but the overall framework is 212.

Guide

21 CFR 212 PET drug cGMP readiness

21 CFR Part 212 was finalized by FDA in 2009 as a stand-alone cGMP regulation for PET drugs — finished pharmaceuticals with a radionuclide of half-life ≤ 110 minutes that are intended for diagnostic or monitoring use. PET producers comply with Part 212 in place of Part 211, plus the USP <823> compendial standard FDA references throughout. This guide is the operator's reading of Part 212 subpart-by-subpart, with the inspection patterns FDA actually pursues during a Pre-Approval Inspection (PAI) and routine surveillance.

Start free trial Free trial, no credit card, onboard in days, not months.

Scope and the 212-vs-211 boundary

212 applies to PET drugs produced for commercial distribution under an approved NDA/ANDA. Investigational PET drugs under a research IND, and academic compounded PET drugs distributed under state pharmacy practice or USP <823>, sit outside 212. Therapeutic radiopharmaceuticals (Lu-177, Ac-225, I-131) and SPECT tracers from generators or reactors fall under 211 with radiopharma-specific guidance — see the 10 CFR 35 and Lu-177-PSMA guides for those.

Subpart B — Personnel and resources (212.10)

Production and QC must be separated organizationally; the production manager cannot release. A named, qualified individual signs the release for each batch — typically titled QA Manager or Quality Unit Head. Training records must show competency in aseptic technique, radiation safety (10 CFR 19/20 in parallel), and the specific synthesis. FDA inspects training records first when sterility findings appear.

Subpart C — Quality assurance (212.20)

QA writes procedures, approves and rejects components and finished product, investigates failures, and approves changes. Crucially the QA function must be able to halt production. The written QA program is a frequent 483 target — generic SOPs that don't reflect the site's actual synthesis modules are flagged.

Subparts D–F — Facilities, equipment, components (212.30–.50)

Hot-cell classification follows USP <823> and FDA guidance: ISO 5 critical zone within at least ISO 7 background, with environmental monitoring frequency matched to risk. Synthesis modules require qualification (IQ/OQ/PQ) and change control on cassette lots. Component testing — particularly precursor and final-product vial — is the second most cited area on PAIs.

Subpart G — Production and process controls (212.60)

Each batch must be produced under a written procedure that yields a product meeting identity, strength, quality, purity, and radiochemical purity. Validation under 212.50(b) is performed on at least three consecutive conforming batches; revalidation triggers on synthesis-module changes, cassette supplier changes, or yield drift outside control limits.

Subpart H — Laboratory controls and conditional release (212.70)

212.70(f) is the conditional-release subsection — FDA explicitly permits release of a PET batch before the sterility test is complete, provided endotoxin, radiochemical purity, radiochemical identity, and appearance are conforming, and the sterility result is followed up post-release. A failing post-release sterility result triggers immediate patient-recall procedures, FDA notification, and a deviation investigation. This is the single highest-risk control point on the floor.

A 90-day path to PAI

Days 0–30: confirm establishment registration and drug listing, finalize the QA Manager appointment, complete IQ/OQ on the synthesis module, run aseptic process simulations. Days 31–60: produce three consecutive validation batches, close any deviations, finalize the stability protocol, and stand up the conditional-release procedure with patient-notification call tree. Days 61–90: mock PAI, close findings, request the PAI. Most first-time PAIs run 3–5 days on site.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

21 CFR Part 11

Part 11 makes electronic records and signatures legally defensible by requiring validation, audit trails, security, signature controls, accurate copies, and retention in line with underlying FDA recordkeeping rules.

GAMP 5

GAMP 5 Second Edition shows how to right-size validation for modern, cloud and agile software while meeting Annex 11 and Part 11 expectations without drowning teams in documents.

CAPA

CAPA is a structured, evidence-based cycle to fix problems, prevent recurrence, and confirm results meet regulatory expectations.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Document control

Versioned SOPs, controlled artwork, periodic review with e-signatures.

QMS

CAPA, deviations, change control, management review wired together.

Audits & CAPA

Findings auto-route to owners with statutory clocks and evidence trail.

Industries this hits hardest

Frequently asked

Can a hospital cyclotron use 212 or do they need 211?

Neither, usually — if the hospital distributes PET drugs only intra-state under state pharmacy practice and USP <823>, they are exempt from 212 and 211. If they ship across state lines under an approved NDA, 212 applies.

Is USP <823> enough for commercial PET production?

No. <823> covers compounding and investigational use; commercial NDA/ANDA distribution requires 212. FDA references <823> within 212 for specific tests (radiochemical identity, radionuclidic purity), but the overall framework is 212.

How does FDA inspect conditional release?

Investigators sample recent batch records and trace the timeline: synthesis end, QC complete, release decision, dispatch, sterility incubation start, sterility readout. Any release decision recorded before all required pre-release tests are conforming is a critical observation.

What's the relationship between 212 and 10 CFR 20?

212 is the drug cGMP; 10 CFR 20 is the NRC (or Agreement State) radiation-protection standard. They run in parallel: FDA inspects 212, NRC or the Agreement State inspects 20. Findings from one can trigger the other's interest, especially for personnel-exposure or contamination events.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →